Acura Pharmaceuticals (ACUR) 10-K 31 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	786,947
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 13.7
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		11,883,339

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 2,681	$ 0
Cash and cash equivalents - restricted (Note 9)	2,500	2,485
Marketable securities (Note 5)	0	10,837
Trade accounts receivable (net of allowances of $7 and $91)	23	42
Collaboration revenue receivable	79	36
Royalty receivable	50	5
Accrued investment income	0	37
Inventories, net (Note 6)	309	276
Prepaid expenses and other current assets	268	417
Total current assets	5,910	14,135
Property, plant and equipment, net (Note 7)	867	1,013
Intangible asset (net of accumulated amortization of $569 and $362) (Note 4)	1,431	1,638
Other assets	0	175
Total assets	8,208	16,961
Current liabilities:
Accounts payable	77	110
Accrued expenses (Note 8)	703	564
Other current liabilities	27	45
Sales returns liability	304	205
Debt - current (Note 9)	2,376	2,320
Total current liabilities	3,487	3,244
Debt - long-term portion (net of debt discount of $98 and $193 and debt issuance costs of $47 and $97 at 2016 and 2015) (Note 9)	2,979	5,430
Accrued interest - non-current portion	559	387
Total liabilities	7,025	9,061
Commitments and contingencies (Note 14)
Stockholders' equity:
Common stock - $.01 par value per share; 100,000 shares authorized, 11,834 and 11,801 shares issued and outstanding at 2016 and 2015, respectively	118	118
Additional paid-in capital	375,763	375,157
Accumulated deficit	(374,698)	(367,310)
Accumulated other comprehensive loss	0	(65)
Total stockholders' equity	1,183	7,900
Total liabilities and stockholders' equity	$ 8,208	$ 16,961

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounts receivable, net of allowances	$ 7	$ 91
Finite-lived intangible assets accumulated amortization	569	362
Long-term debt, net of debt discount	98	193
Debt Instrument Issuance Cost	$ 47	$ 97
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	11,834	11,801
Common stock, shares outstanding	11,834	11,801

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues:
License fee revenue	$ 3,500	$ 5,250
Milestone revenue	0	2,500
Collaboration revenue	392	170
Royalty revenue	149	5
Product sales, net	423	662
Total revenues, net	4,464	8,587
Cost and expenses:
Cost of sales (excluding inventory write-down)	451	656
Inventory reserve expense for write-downs (Note 6)	26	330
Research and development	4,028	2,608
Selling, marketing, general and administrative	6,516	8,994
Total costs and expenses	11,021	12,588
Operating loss	(6,557)	(4,001)
Non-Operating income (expense):
Investment income	60	166
Interest expense (Note 9)	(893)	(1,157)
Other income	2	3
Total other expense, net	(831)	(988)
Loss before provision for income taxes	(7,388)	(4,989)
Provision for income taxes	0	0
Net loss	(7,388)	(4,989)
Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities	65	(52)
Comprehensive loss	$ (7,323)	$ (5,041)
Net loss per share:
Basic	$ (0.62)	$ (0.46)
Diluted	$ (0.62)	$ (0.46)
Weighted average shares outstanding:
Basic	11,870	10,796
Diluted	11,870	10,796

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2014	$ 5,052	$ 98	$ 367,288	$ (362,321)	$ (13)
Balance (in shares) at Dec. 31, 2014		9,770
Net loss	(4,989)	$ 0	0	(4,989)	0
Other comprehensive loss	(52)	0	0	0	(52)
Share-based compensation	606	0	606	0	0
Net distribution of common stock pursuant to restricted stock unit award plan	0	$ 0	0	0	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		19
Modification to warrants issued with promissory notes	33	$ 0	33	0	0
Issuance of common stock under “at the market” offerings, net of offering costs of $8	217	$ 0	217	0	0
Issuance of common stock under “at the market” offerings, net of offering costs of $8 (in shares)		54
Issuance of common stock under registered direct offering, net of offering costs of $603	7,033	$ 20	7,013	0	0
Issuance of common stock under registered direct offering, net of offering costs of $603 (in shares)		1,958
Balance at Dec. 31, 2015	7,900	$ 118	375,157	(367,310)	(65)
Balance (in shares) at Dec. 31, 2015		11,801
Net loss	(7,388)	$ 0	0	(7,388)	0
Other comprehensive loss	65	0	0	0	65
Share-based compensation	588	0	588	0	0
Net distribution of common stock pursuant to restricted stock unit award plan	18	$ 0	18	0	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		33
Balance at Dec. 31, 2016	$ 1,183	$ 118	$ 375,763	$ (374,698)	$ 0
Balance (in shares) at Dec. 31, 2016		11,834

CONSOLIDATED STATEMENTS OF STO6

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Direct Offering [Member]
Net offering costs	$ 603
Market Offering [Member]
Net offering costs	$ 8

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash Flows from Operating Activities:
Net loss	$ (7,388)	$ (4,989)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	138	125
Provision to reduce inventory to net realizable value	26	330
Provision for sales returns	99	267
Provision for fixed asset impairment	82	0
Share-based compensation	588	606
Amortization of debt discount and debt issuance costs	145	186
Amortization of bond premium in marketable securities	31	127
Amortization of intangible asset	207	207
Gain on sales of marketable securities	(2)	(3)
Loss on disposals of property, plant and equipment	1	19
Changes in assets and liabilities:
Accounts receivable, net	19	(28)
Collaboration revenue receivable	(43)	(36)
Royalty receivable	(45)	(5)
Accrued investment income	37	29
Inventories	(59)	(302)
Prepaid expenses and other current assets	149	54
Other current deferred assets	0	218
Other assets	175	(175)
Accounts payable	(33)	(107)
Accrued expenses	139	(4)
Deferred revenue	0	(353)
Accrued interest - current and long term	172	127
Other current liabilities	(1)	19
Net cash used in operating activities	(5,563)	(3,688)
Cash Flows from Investing Activities:
Purchases of marketable securities	0	(3,522)
Proceeds from sales and maturities of marketable securities	10,873	3,830
Additions to property, plant and equipment	(75)	(214)
Proceeds from disposals of property, plant and equipment	0	14
Net cash provided by investing activities	10,798	108
Cash Flows from Financing Activities:
Proceeds from distribution of restricted stock units	1	1
Proceeds from ATM offering	0	225
Proceeds from Registered Direct offering	0	7,636
Transaction costs from ATM offering	0	(603)
Transaction costs from Registered Direct offering	0	(8)
Principal payments on debt	(2,540)	(1,960)
Net cash (used in) provided by financing activities	(2,539)	5,291
Net increase in cash and cash equivalents	2,696	1,711
Cash and cash equivalents at beginning of year	2,485	774
Cash and cash equivalents at end of year	5,181	2,485
Cash paid during the year for:
Interest on term loan with Oxford Finance LLC	576	844
Income taxes, net of refunds	$ 0	$ 0

CONSOLIDATED STATEMENTS OF CAS8

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Supplemental Disclosure of Noncash Financing Activities:
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 2.52
Fair Value Adjustment of Warrants | $	$ 33
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	60

OPERATIONS AND SUMMARY OF SIGNI

OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Description Of Operation And Summary Of Significant Accounting Policies Disclosure [Abstract]
OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principal Operations Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® and Limitx™ Technologies are intended to address methods of product tampering associated with opioid abuse while our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine into methamphetamine. · Oxaydo® Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first and only approved immediate-release oxycodone product in the United States with abuse deterrent labeling. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo®. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015. See Note 4. · Nexafed® Tablets (30mg pseudoephedrine) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine and acetaminophen), utilizing the Impede Technology, were launched by us into the United States market in December 2012 and February 2015, respectively. We have multiple pseudoephedrine products in development utilizing our Impede Technology. On June 15, 2015, we and Bayer Healthcare LLC entered into a License and Development Agreement pursuant to which we granted Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine – containing product and providing for the joint development of such product using our Impede Technology for the U.S. market. On March 16, 2017, we and MainPointe Pharmaceuticals, LLC, or MainPointe, entered into a License, Commercialization and Option Agreement, or the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology in the United States and Canada to commercialize our Nexafed products. The MainPointe Agreement also grants MainPointe the option to expand the licensed territory to the European Union, Japan and South Korea and to add additional pseudoephedrine-containing products utilizing our Impede technology. See Note 4. · Our third abuse deterrent technology, Limitx, is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. We have completed our first clinical study, Study AP-LTX-400, of our lead Limitx immediate release oral abuse deterrent drug candidate using the opioid hydromorphone HCI (LTX-04). Study AP-LTX-400, or Study 400, was a two cohort, open label, crossover design pharmacokinetic study in healthy adult subjects. The FDA has designated the development program for LTX-04 as Fast Track, which is designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. We are also developing an immediate-release hydrocodone bitartrate with acetaminophen product utilizing our Limitx Technology. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The going concern basis of presentation assumes that we will continue in operation for the next twelve months and will be able to realize our assets and discharge our liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. 2.5 2.7 0.7 374.7 6.6 7.4 We have suffered recurring losses from operations and have not generated positive cash flows from operations. 2.5 In addition to our $ 2.5 However, these factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. To fund further operations and product development activities beyond mid-2017, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. The Company intends to explore a variety of capital raising and other transactions to provide additional funding to continue operations. These include a registered public offering of the Company’s common stock, for which the Company filed a registration statement on Form S-1 with the SEC on February 3, 2017, and potential private offerings of common stock to institutional investors. The Company is also actively seeking a licensing partner for its Limitx Technology, with the objective of receiving an upfront license fee, development milestone payments and royalties on the net sales of products utilizing the Limitx Technology, similar to the Egalet and Bayer Agreements. The Company is also exploring licensing or selling select assets and intellectual property in an effort to raise capital and reduce operating expenses. Finally, the Company is evaluating the potential for a strategic transaction which may involve the Company being acquired in a merger or asset purchase transaction. No assurance can be given that we will be successful in completing any one or more of such transactions on acceptable terms, if at all, or if completed, that such transactions will provide payments to the Company sufficient to fund continued operations. In the absence of the Company’s completion of one or more of such transactions, there will be substantial doubt about the Company’s ability to continue as a going concern and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements include the accounts of our wholly-owned subsidiary, Acura Pharmaceutical Technologies Inc., after elimination of intercompany accounts and transactions. Amounts presented have been rounded to the nearest thousand, where indicated, except share and per share data. The equity amounts and all share and per share data of the Company have been retroactively adjusted to reflect a one-for-five reverse stock split effected by us on August 28, 2015. Certain reclassifications have been made to the prior year’s amounts to conform to the current year’s presentation. Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based on such periodic evaluations. The Company considers cash and cash equivalents to include cash in financial institutions and money market funds, and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Our cash and cash equivalents are governed by our investment policy as approved by our Board of Directors. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature. The Company did not have marketable securities at December 31, 2016. The Company’s marketable securities at December 31, 2015 primarily consisted of corporate debt securities and exchange-traded funds. Our marketable securities are governed by our investment policy as approved by our Board of Directors. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices or net asset value. Unrealized temporary adjustments to fair value are included in a separate component of stockholders’ equity as unrealized gains and losses and reported as a component of accumulated other comprehensive income (loss). No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, trade accounts payable, and our long-term debt. The carrying amounts of these financial instruments, other than marketable securities and our long-term debt, are representative of their respective fair values due to their relatively short maturities. The Company has not been able to measure the fair value of long-term debt due to a very limited marketplace having little or no market activity for this debt placement but given the change in the Company’s credit risk, the Company believes the fair value of long-term debt is below its carrying value. As discussed above, marketable securities are recorded at fair value. Credit Risk : Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company’s excess cash is invested in accordance with the investment policy approved by our Board of Directors that seeks a combination of both liquidity and safety of principal using diversification of investments, through investments such as investment grade corporate debt securities with varying maturities. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, and marketable securities. Customers: We launched our first Impede Technology product, Nexafed®, in the United States in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. Our accounts receivable arise from our sales of our Nexafed product line and represent amounts due from wholesalers in the health care and pharmaceuticals industries and from chain drug stores. The Company has performed a credit evaluation of its customers and may maintain an allowance for potentially uncollectable accounts. We have not experienced any losses on uncollectable accounts in 2016 or 2015. 10 10 Customer 2016 2015 Rite Aid Corporation 55 % 54 % Cardinal Health, Inc. 13 % 14 % McKesson Corporation 10 % * Trade accounts receivable from certain of our customers at December 31, 2016 and 2015 accounting for 10% or more of our gross accounts receivable is presented below. Trade accounts receivable from customers designated with an ” ** ” accounted for less than 10% of our gross trade accounts receivable. Customer 2016 2015 AmerisourceBergen Corporation 35 % ** McKesson Corporation 24 % 11 % Cardinal Health, Inc. 19 % ** The Kroger Co. 18 % ** Rite Aid Corporation ** 68 % Inventories at December 31, 2016 consist of raw materials to be used in the manufacture to integrate Impede 2.0 technology into our commercially available Nexafed 30mg tablets, and finished goods held for distribution and sale on our Nexafed® product line. Inventories at December 31, 2015 consisted of finished goods held for distribution and sale on our Nexafed® product line. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). The Company writes down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results. Our purchases of active pharmaceutical ingredients and raw materials required for our development and clinical trial manufacture of product candidates utilizing our Aversion®, Impede® or Limitx Technologies are expensed as incurred. Property, plant and equipment are stated at cost, less accumulated depreciation. We have no leasehold improvements. Betterments are capitalized and maintenance and repairs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation is removed from the respective accounts. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. depreciable assets are: 10 40 Land and improvements 20 40 Machinery and equipment 7 10 Scientific equipment 5 10 Computer hardware and software 3 10 Deferred debt issuance costs include costs of debt financing undertaken by the Company, including legal fees, placement fees and other direct costs of the financing. Debt discount is the value attributable to warrants issued in conjunction with the financing. Debt issuance costs and debt discount are amortized into interest expense over the term of the related debt using the effective interest method. See Recent Accounting Pronouncements In December 2014, the Company entered into an agreement with Purdue Pharma to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered on the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering into an agreement whereby Acura conceded Purdue’s claim of priority in exchange for certain financial consideration to Acura including an immediate non-refundable payment of $ 500 250 In January 2015, the Company entered into a Collaboration and License Agreement to commercialize Oxaydo tablets (formerly known as Oxecta) utilizing our Aversion® Technology with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”). Egalet paid us $5.0 million upon signing the Egalet Agreement In October 2016, the Company entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using two of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm paid us $ 3.5 Milestone revenue is contingent upon the achievement of certain pre-defined events in the development agreements. Milestone payments are recognized as revenue upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to that milestone. Milestone payments are triggered either by the results of our research and development efforts or by events external to us, such as regulatory approval to market a product. As such, the milestones are substantially at risk at the inception of an agreement, and the amounts of the payments assigned thereto are commensurate with the milestone achieved. In addition, upon the achievement of a milestone event, we have no future performance obligations related to that milestone payment. Each milestone payment is non-refundable and non-creditable when made and is recognized as revenue when received. In October 2015, Egalet paid us a $ 2.5 Collaboration revenue is derived from reimbursement of development expenses, such as under our agreement with Bayer, and are recognized when costs are incurred pursuant to the agreements. The ongoing research and development services being provided under the collaboration are priced at fair value based upon the reimbursement of expenses incurred pursuant to the collaboration agreements. We recognized $ 392 In connection with our Collaboration and License Agreement with Egalet to commercialize Oxaydo tablets we will receive a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year over the term of the agreement (excluding net sales resulting from any co-promotion efforts by us). We recognize royalty revenue each calendar quarter based on net sales reported to us by Egalet in accordance with the agreement. Egalet’s first commercial sale of Oxaydo occurred in October 2015 and we have recorded royalties of $149 thousand and $ 5 Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. We sell our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products are sold subject to the right of return usually for a period of up to twelve months after the product expiration. Both products had an initial shelf life of twenty-four months from the date of manufacture, which shelf life has been extended to thirty-six months for Nexafed product supplied to us during 2016 from one of the Company’s contract manufacturers. Given the limited sales history of our Nexafed products, we could not reliably estimate expected returns of the product at the time of shipment to certain customers. During 2014, we continued deferring the recognition of revenue. During the first quarter of 2015, we determined we had obtained sufficient sales returns history to reasonably estimate future product returns from those customers. We recorded a one-time adjustment in the first quarter of 2015 to recognize revenue that had previously been deferred, resulting in additional net revenues of $ 314 120 255 304 205 The Company records the cost of its advertising efforts when services are performed or goods are delivered. The Company records shipping and handling costs in selling expenses. The amounts recorded from the sales of Nexafed® were not material. Long-lived assets such as the intangible asset and property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of the assets to be held and used is measured by a comparison of the carrying amount of the asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying value of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. We recorded an impairment charge of $ 82 Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO’s based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. During 2015, we entered into a cancelable arrangement for contract manufacturing services on a project to integrate Impede 2.0 technology into our commercially available Nexafed 30mg tablet while moving supply to an alternate contract manufacturer. Approximately $ 50 0.2 We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 12. We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost. Our share-based compensation expense recognized in the Company’s results of operations from all types of instruments issued comprised the following (in thousands): Year ended December 31, 2016 2015 Research and development: Stock option awards $ 167 $ 158 RSU awards - - $ 167 $ 158 Selling, general and administrative: Stock option awards 301 384 RSU awards 143 95 $ 444 $ 479 Total share-based compensation expense $ 611 $ 637 Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that, under GAAP, are included in comprehensive income (loss), but excluded from net income (loss) as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company’s other comprehensive income (loss) is composed of unrealized gains (losses) on certain holdings of marketable securities, net of any realized gains (losses) included in net income (loss). We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and the income tax basis of assets and liabilities and are measured using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At December 31, 2016 and 2015, 100% of all remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized. Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 12). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2016 or 2015 as the Company reported a net loss for the years and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive. Years ended December 31, 2016 2015 EPS – basic Numerator: net loss $ (7,388) $ (4,989) Denominator (weighted): Common shares 11,834 10,777 Vested RSUs 36 19 Basic weighted average shares outstanding 11,870 10,796 EPS - basic $ (0.62) $ (0.46) EPS – assuming dilution Numerator: net loss $ (7,388) $ (4,989) Denominator (weighted): Common shares 11,834 10,777 Vested RSUs 36 19 Stock options - - Common stock warrants - - Diluted weighted average shares outstanding 11,870 10,796 EPS - diluted $ (0.62) $ (0.46) Excluded dilutive securities: Common stock issuable (non weighted): Stock options 1,397 1,198 Common stock warrants 60 60 Total excluded potentially dilutive shares 1,457 1,258

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 3 – RECENT ACCOUNTING PRONOUNCEMENTS Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In August 2014, the FASB issued ASU No. 2014-15, “ Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Revenue from Contracts with Customers In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the transition method we will utilize to adopt the standard for use in 2018. Presentation of Debt Issuance Costs In April 2015, the FASB issued ASU No. 2015-03, “Interest Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.” Leases In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018 but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its consolidated financial statements and related disclosures.

LICENSE, DEVELOPMENT, AND COMME

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS	12 Months Ended
	Dec. 31, 2016
Research and Development Disclosure [Abstract]
LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT	NOTE 4 – LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS KemPharm Agreement On October 13, 2016, we and KemPharm Inc. (“KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities. Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $ 3.5 1.0 The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm. Bayer Agreement On June 15, 2015, we and Bayer entered into a License and Development Agreement (the “Bayer Agreement”) granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine–containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. The Bayer Agreement also grants Bayer first right to negotiate a license to the Impede Technology for certain other products. We and Bayer have formed a joint development committee to coordinate development of the Bayer Licensed Product. We are eligible to receive reimbursement of certain of our development costs, success-based development and regulatory milestones payments, and low mid-single digit royalties on net sales of the Bayer Licensed Product in countries with patent coverage and a reduced royalty elsewhere. The term of the Bayer Agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the Bayer Licensed Product on a royalty free basis. Either party may terminate the Bayer Agreement in its entirety if the other party materially breaches the Bayer Agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the Bayer Agreement immediately prior to completion of our development obligations or at any time upon six (6) months prior written notice thereafter. We may terminate the Bayer Agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the Bayer Licensed Product for a certain period of time. Egalet Agreement On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015. In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Egalet will pay a substantial majority of the fees and expenses and we will pay for the remaining fees and expense relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Egalet will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion. Egalet paid us a $ 5.0 2.5 one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period. MainPointe Agreement On March 16, 2017, we and MainPointe Pharmaceuticals, LLC, or MainPointe, entered into a License, Commercialization and Option Agreement, or the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed products in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement. On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $ 2.5 425,000 7.5 MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $ 1 500,000 250,000 In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500,000 per product (for all product strengths). If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750,000 per product. If the territory is expanded after the payment of the $500,000 product option fee, a one-time $250,000 fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate. The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura. Terminated Pfizer Agreement In 2007, we entered into License, Development and Commercialization Agreement for Oxaydo (named Oxecta™ under a Pfizer trademark) and other Aversion opioid development products with King Pharmaceuticals Research and Development, Inc., which became a subsidiary of Pfizer in 2011 (the “Pfizer Agreement”). In April 2014, we entered into two letter agreements with Pfizer providing for the termination of the Pfizer Agreement and the return to us of Oxaydo and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $ 2.0 9.7 207 207 260

INVESTMENTS IN MARKETABLE SECUR

INVESTMENTS IN MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS IN MARKETABLE SECURITIES	The Company did not have investments in marketable securities at December 31, 2016. December 31, 2015 Marketable securities: Corporate bonds — maturing within 1 year $ 3.1 Corporate bonds — maturing after 1 year and through March 2017 0.4 Exchange-traded funds 7.3 Total marketable securities $ 10.8 The Company’s marketable securities are classified as available-for-sale and are recorded at fair value based on quoted market prices or net asset value using the specific identification method. The purchase cost of corporate bonds may include a purchase price premium or discount which will be amortized or accreted against earned interest income to the maturity date of the bond. Our marketable securities are classified as current in the Company’s Consolidated Balance Sheets as they may be sold within one year in response to changes in market prices or interest rates, to realign our investment concentrations or to meet our working capital needs. December 31, 2015 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value Available-for-sale: Corporate bonds $ 3.6 $ - $ (0.1) $ 3.5 Exchange-traded funds 7.3 - - 7.3 Total - Current $ 10.9 $ - $ (0.1) $ 10.8 Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted market prices in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable market-based inputs or unobservable inputs that are corroborated by market data. Fair values determined based on Level 3 inputs utilize unobservable inputs reflecting the reporting entity’s own assumptions. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Corporate bonds 3.5 - 3.5 - Exchange-traded funds 7.3 7.3 - - Total $ 10.8 $ 7.3 $ 3.5 $ - Accumulated Other Comprehensive Income (Loss) Unrealized gains or losses on marketable securities are recorded in accumulated other comprehensive income (loss). The Company did not have investments in marketable securities at December 31, 2016. Accumulated other comprehensive income (loss) at December 31, 2015 consisted of unrealized losses on securities of $ 65

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 6 – INVENTORIES Inventories at December 31, 2016 consist of raw materials to be used in the manufacture to integrate Impede 2.0 technology into our commercially available Nexafed 30mg tablets, and finished goods held for distribution and sale on our Nexafed product line. Inventories at December 31, 2015 consist of finished goods held for distribution and sale on our Nexafed product line. During 2014, we purchased selected raw and packaging material inventories for $ 260 Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred. December 31, 2016 2015 Raw materials $ 98 $ - Finished goods 243 346 Total inventory 341 346 Less: inventory reserve - finished goods (32) (70) Net inventory $ 309 $ 276 2016 2015 Beginning of year $ 70 $ - Reserve expense - raw and packaging - 260 Reserve expense - finished goods 26 70 96 330 Inventory write-offs - raw and packaging - (260) Inventory write-offs - finished goods (64) - End of year $ 32 $ 70

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 7 – PROPERTY, PLANT AND EQUIPMENT December 31, 2016 2015 Building and improvements $ 1,273 $ 1,265 Scientific equipment 598 598 Computer hardware and software 109 124 Machinery and equipment 568 508 Land and improvements 162 162 Other personal property 70 70 Office equipment 27 27 2,807 2,754 Less: impairment reserve (82) (-) Less: accumulated depreciation (1,858) (1,741) Total property, plant and equipment, net $ 867 $ 1,013 Depreciation expense was approximately $ 0.1

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 8 – ACCRUED EXPENSES December 31, 2016 2015 Professional services $ 232 $ 171 Other fees and services 95 64 Payroll, payroll taxes and benefits 116 101 Clinical and regulatory services 233 92 Marketing, advertising, and promotion 10 115 Property taxes 16 15 Franchise taxes 1 6 $ 703 $ 564

DEBT

DEBT	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
DEBT	NOTE 9 – DEBT On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $ 10.0 8.35 13.35 260 December 1, 2018 4.5 60 7.98 400 December 27, 2020 Expected dividend yield 0.0 % Risk-free interest rate 2.4 % Expected volatility 92 % Expected term (years) 7 On January 7, 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the Warrants was lowered from $ 7.98 2.52 33 2.5 5.0 On October 13, 2016, we and Oxford entered into a second amendment to the Loan Agreement (the “Second Amendment”). Pursuant to the Second Amendment, (i) the requirement that we maintain a $ 2.5 5.0 6.0 3.0 On March 16, 2017, we and Oxford entered into a third amendment to the Loan Agreement, or the Third Amendment. Pursuant to the Third Amendment (i) we granted Oxford a lien on our intellectual property, (ii) Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s going concern opinion for our 2016 financial statements and (iii) Oxford consented to the terms of the MainPointe Agreement. Per the term loan agreement, an audit opinion with an explanatory paragraph noting substantial doubt about the Company’s ability to continue in business is deemed to violate the Unqualified Audit Opinion Covenant. The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 1 795 559 387 The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $ 50 100 231 10.16 The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non–payment defaults, covenant defaults, a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults. Our debt at December 31, 2016 is summarized below (in thousands): Current Debt Current Long-term Total Balance at Dec 31, 2015 $ 2,320 $ 5,720 $ 8,040 Principal payments (2,540) - (2,540) Classification 2,741 (2,741) - Balance at Dec 31, 2016 $ 2,521 $ 2,979 $ 5,500 Debt Discount Current Long-term Total Balance at Dec 31, 2015 $ - $ (193) $ (193) Amortization expense - 95 95 Classification (98) 98 - Balance at Dec 31, 2016 $ (98) $ - $ (98) Deferred Debt Issuance Costs Current Long-term Total Balance at Dec 31, 2015 $ - $ (97) $ (97) Amortization expense - 50 50 Classification (47) 47 - Balance at Dec 31, 2016 $ (47) $ - $ (47) Current Debt, net at Dec 31, 2016 $ 2,376 $ 2,979 $ 5,355 2016 2015 Interest expense: Term Loan $ 748 $ 971 Debt discount 95 121 Debt issue costs 50 65 Total interest expense $ 893 $ 1,157 The annual principal payments of the debt at December 31, 2016 are as follows: Annual Principal Payments Year (in thousands) 2017 $ 2,521 2018 2,979 Total $ 5,500

EQUITY FINANCINGS

EQUITY FINANCINGS	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
EQUITY FINANCING	NOTE 10 – EQUITY FINANCINGS Our universal shelf registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (“SEC”) on March 15, 2013. On April 18, 2013, we filed a prospectus supplement with the SEC pursuant to which we could sell shares of our common stock from time to time in “at the market” offerings and certain other transactions, having sales proceeds of up to $ 13 54 225 8 217 On June 30, 2015, we entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (“Roth”), pursuant to which we engaged Roth to act as sole placement agent in a registered direct offering (the “Offering”) of 1.958 01 1.958 3.90 7.64 Pursuant to the terms of the Placement Agency Agreement, we paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering 496 35 7.0

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS	12 Months Ended
	Dec. 31, 2016
Stockholders Equity Note [Abstract]
COMMON STOCK WARRANTS	NOTE 11 – COMMON STOCK WARRANTS We have outstanding common stock purchase warrants (“warrants”) exercisable for 60 2.52 10.0 December 31, 2016 2015 WAvg WAvg Exercise Exercise Number Price Number Price Outstanding, beginning 60 $ 2.52 60 $ 7.98 Issued - - - - Exercised - - - - Expired - - - - Modification - - - (5.46) Outstanding, ending 60 $ 2.52 60 $ 2.52

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
EMPLOYEE BENEFIT PLANS	NOTE 12 – EMPLOYEE BENEFIT PLANS 401(k) and Profit-Sharing Plan We have a 401(k) and Profit-Sharing Plan (the “Plan”) for our employees. Employees may elect to make a basic contribution of up to 80 Stock Option Plans We maintain various stock option plans. Years Ended December 31, 2016 2015 Weighted Weighted Number Average Average of Exercise Number of Exercise Options Price Options Price Outstanding, beginning 1,198 $ 15.67 911 $ 20.70 Granted 199 0.92 315 2.01 Exercised - - - - Forfeited or expired - - (28) 26.75 Outstanding, ending 1,397 $ 15.67 1,198 $ 15.67 Exercisable, ending 1,062 $ 17.41 814 $ 22.04 Number of Weighted Options Not Average Fair Exercisable Value Outstanding at December 31, 2015 384 $ 1.85 Granted 199 0.92 Vested (248) 1.89 Forfeited - - Outstanding at December 31, 2016 335 $ 1.18 We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. Historically, the majority of our stock options have been held until their expiration date. 2016 2015 Expected dividend yield 0.0 % 0.0 % Risk-free interest rates 2.3 % 2.2 % Average expected volatility 85 % 89 % Expected term (years) 10 10 Weighted average grant date fair value $ 0.77 $ 1.72 The intrinsic value of the option awards which were vested and outstanding at December 31, 2015 was $ 6 400 Restricted Stock Unit Award Plan We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”) and a 2005 Restricted Stock Unit Award Plan (the “2005 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award. Years Ended December 31, 2016 2015 Number of Number of Number of Vested Number of Vested RSUs RSUs RSUs RSUs Outstanding, beginning 45 45 29 29 Granted 88 - 42 - Distributed (42) (42) (26) (26) Vested - 88 - 42 Forfeited or expired - - - - Outstanding, ending 91 91 45 45 2014 Restricted Stock Unit Award Plan Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to 400 241 Information about the awards under the 2014 RSU Plan is as follows: · On May 1, 2014, we awarded approximately 7 50 25 26 · On January 2, 2015, we awarded approximately 10 25 45 · On January 4, 2016, we awarded approximately 22 25 27 66 · On January 3, 2017, we awarded approximately 60 25 Information about the distribution of shares under the 2014 RSU Plan is as follows: · On January 2, 2015, 26 4 26 19 7 · On January 4, 2016, 1 42 2 42 33 9 · On January 3, 2017, 1 66 1 22 67 49 18

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 13 – INCOME TAXES Provision for Income Taxes December 31, 2016 2015 Benefit at U.S. statutory 34% tax rate $ (2,512) $ (1,696) State taxes (benefit), net of federal effect 49 41 Research and development tax credits - - Share-based compensation 159 184 Other 2 11 Change in valuation allowance 2,302 1,460 Provision for income taxes $ - $ - Deferred Tax Assets and Valuation Allowance Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $ 47.2 138.8 34 2.1 2017 2036 5.6 0.6 1.2 0.2 The components of our deferred tax assets are as follows: December 31, 2016 2015 (in thousands) Deferred tax assets: Estimated future value of NOLs - Federal $ 47,192 $ 52,772 - State 2,135 2,050 Research and development tax credits 1,320 1,394 Share-based compensation 57 38 Other, net 332 368 Total deferred taxes 51,036 56,622 Valuation allowance (51,036) (56,622) Net deferred tax assets $ - $ - Realization of deferred tax assets is dependent upon future earnings, if any, and the timing and amount of which may be uncertain. Valuation allowances are placed on deferred tax assets when uncertainty exists on their near term utilization. We make periodic reviews of our valuation allowances and fluctuations can occur. Those fluctuations may be reflected as income tax expenses or benefits in the period they occur. We continue to maintain full valuation allowance against all of our deferred tax assets at December 31, 2016 due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that amounts of our deferred tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and a benefit from income taxes in such period would be recognized. Uncertainty in Income Taxes We adopted FASB’s statement regarding accounting for uncertainty in income taxes which defined the threshold for recognizing the benefits of tax-return positions in the consolidated financial statements as “more-likely-than-not” to be sustained by the taxing authorities. Our adoption of the standard did not result in establishing a contingent tax liability reserve or a corresponding charge to retained earnings. At each of December 31, 2016 and 2015, we had no liability for income tax associated with uncertain tax positions. If in the future we establish a contingent tax liability reserve related to uncertain tax positions, our practice will be to recognize the interest in interest expense and the penalties in other non-operating expense. The Company files federal and state income tax returns and in the normal course of business the Company is subject to examination by these taxing authorities. As of December 31, 2016, the Company’s tax years 2013, 2014 and 2015 are subject to examination by the taxing authorities. With few exceptions, we believe the Company is no longer subject to U.S. Federal, State and local examinations by taxing authorities for years before 2013.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 – COMMITMENTS AND CONTINGENCIES Reglan ® /Metoclopramide Litigation Halsey Drug Company, as predecessor to us, has been named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, we were served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide. In the Pennsylvania action, over 200 150 50 445 In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 19 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing In Pennsylvania, and California, Generic Defendants, including us, also filed dispositive motions based on the Mensing In Pennsylvania, on November 18, 2011, the trial court denied Generic Defendants’ dispositive preemption motions, without prejudice. In July 2013, the Pennsylvania Superior Court issued an adverse decision, and a subsequent appeal to the Pennsylvania Supreme Court was denied. On December 16, 2014, the Generic Defendants filed a Joint Petition for Certiorari with the United States Supreme Court captioned Teva Pharmaceuticals USA, Inc. et al. v. Dorothy Bentley, et al. From July, 2015 to date, the court has taken procedural steps to narrow this litigation, including requests for plaintiffs to voluntarily discontinue cases, such as those filed against us, where there is no case-specific product identification. The trial court proceedings were stayed on January 12, 2017. We are in the process of obtaining voluntary dismissal without prejudice of all of the Pennsylvania cases pending against us. We expect that the Court will approve these dismissals during the second quarter of 2017 and should finally dismiss the Pennsylvania-based litigation against us with prejudice later this year. Legal fees related to this matter are currently covered by our insurance carrier. In California, the trial court entered a May 25, 2012 Order denying Generic Defendants’ dispositive preemption motions. The Generic Defendants’ appeals from this order were denied by the California appellate courts. In May 2014, the California Court denied a subsequent demurrer and motion to strike seeking dismissal of plaintiffs’ manufacturing defect and defective product claims to the extent that they are barred by federal preemption based upon the June 2013 Bartlett As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of December 31, 2016 and we are presently unable to determine if any potential loss would be covered by our insurance carrier. Purdue Pharma Settlement In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007 (the “ 007 patent”). In April 2016, Purdue commenced a second patent infringement lawsuit against us and Egalet in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s newly issued U.S. Patent No. 9,308,171 (the “171 Patent”). The actions regarding the 007 Patent and the 171 Patent are collectively referred to as the “Actions”. On April 6, 2016, we filed a petition for Inter Partes Review (the “IPR Review”) with the U.S. Patent and Trademark Office (“USPTO”) seeking to invalidate Purdue’s 007 Patent. On May 20, 2016, Purdue on behalf of themselves and certain affiliates, Egalet Corporation, on behalf of itself and its affiliates and we, on behalf of ourselves and our affiliates entered into a settlement agreement (the “Settlement Agreement”) to settle the Actions and the IPR Review. Under the Settlement Agreement the parties dismissed or withdrew the Actions, requested that the USPTO terminate the IPR Review and exchanged mutual releases. No payments were made under the Settlement Agreement. The Settlement Agreement also provides that Purdue will not, in the future, assert certain Purdue U.S. patents, including the 007 Patent, the 171 Patent and related technologies (the “Purdue Patents”) against any Acura Settlement Product or Egalet Settlement Product (except generally in an action or interference by Acura or Egalet challenging a Purdue Patent). Acura Settlement Products and Egalet Settlement Products are certain immediate-release and extended-release products, including Oxaydo. In addition, the Settlement Agreement provides that Purdue will not challenge, with certain exceptions, the Acura/Egalet Patents with respect to the Purdue Settlement Products (as defined below) and that Purdue provides Acura and/or Egalet certain waivers of non-patent marketing exclusivity with respect to Purdue Settlement Products. The Settlement Agreement also provides that Acura and Egalet will not, in the future, assert certain Acura and/or Egalet U.S. patents (the “Acura/Egalet Patents”), including Acura’s Aversion® Technology patents, against any Purdue Settlement Products (except generally in an action or interference by Purdue challenging an Acura/Egalet Patent). Purdue Settlement Products are certain immediate-release and extended-release products. In addition, the Settlement Agreement provides that Acura and Egalet will not challenge, with certain exceptions, the Purdue Patents with respect to the Acura Settlement Products and Egalet Settlement Products and that Acura and Egalet provide Purdue certain waivers of non-patent marketing exclusivity with respect to the Acura Settlement Products and Egalet Settlement Products. In addition, Purdue has certain rights to negotiate to exclusively distribute an authorized generic version of certain Egalet Settlement Products, including, in some circumstances, Oxaydo® and other products using Acura’s Aversion® Technology if licensed to Egalet. The Settlement Agreement specifically excludes our patents related to our Impede® and Limitx™ technologies from the scope of the Acura/Egalet Patents under the Settlement Agreement. In December 2014, the Company entered into an agreement with Purdue Pharma L.P. to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered upon the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering an agreement whereby the Company conceded Purdue Pharma’s claim of priority in exchange for certain financial consideration to us including an immediate non-refundable payment of $ 500 250 Egalet Agreement On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015. In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Egalet will pay a substantial majority of the expenses and we will pay for the remaining fees and expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Egalet will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion. At December 31, 2016, we have accrued approximately $ 95 Facility Lease The Company leases administrative office space in Palatine, Illinois under a lease for $ 25 March 31, 2017

SUBSEQUENT EVENT

SUBSEQUENT EVENT	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 15 – SUBSEQUENT EVENT On March 16, 2017, we and MainPointe Pharmaceuticals, LLC or MainPointe, entered into a License, Commercialization and Option Agreement, or the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed products in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement. On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $ 2.5 425,000 7.5 MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $ 1 500,000 250,000 In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500,000 per product (for all product strengths). If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750,000 per product. If the territory is expanded after the payment of the $500,000 product option fee, a one-time $250,000 fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate. The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura.

SUPPLEMENTARY DATA - QUARTERLY

SUPPLEMENTARY DATA - QUARTERLY FINANCIAL DATA (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
SUPPLEMENTARY DATA - QUARTERLY FINANCIAL DATA	SUPPLEMENTARY DATA - QUARTERLY FINANCIAL DATA (Unaudited) For Three Month Periods Ended Mar. 31, June 30, Sept. 30, Dec. 31, 2016 2016 2016 2016 Net revenues $ 224 $ 257 $ 218 $ 3,765 Operating expenses 3,362 3,336 2,287 2,036 Operating (loss) income (3,138) (3,079) (2,069) 1,729 Net (loss) income $ (3,384) $ (3,288) $ (2,250) $ 1,534 Basic (loss) income per share $ (0.28) $ (0.28) $ (0.19) $ 0.13 Diluted (loss) income per share $ (0.28) $ (0.28) $ (0.19) $ 0.13 For Three Month Periods Ended Mar. 31, June 30, Sept. 30, Dec. 31, 2015 2015 2015 2015 Net revenues $ 5,357 $ 341 $ 210 $ 2,679 Operating expenses 3,845 2,739 2,615 3,389 Operating income (loss) 1,512 (2,398) (2,405) (710) Net loss $ 1,239 $ (2,663) $ (2,649) $ (916) Basic income (loss) per share $ 0.13 $ (0.28) $ (0.23) $ (0.08) Diluted income (loss) per share $ 0.13 $ (0.28) $ (0.23) $ (0.08)

SUMMARY OF SIGNIFICANT ACCOUN25

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of our wholly-owned subsidiary, Acura Pharmaceutical Technologies Inc., after elimination of intercompany accounts and transactions. Amounts presented have been rounded to the nearest thousand, where indicated, except share and per share data. The equity amounts and all share and per share data of the Company have been retroactively adjusted to reflect a one-for-five reverse stock split effected by us on August 28, 2015.
Reclassifications	Reclassifications Certain reclassifications have been made to the prior year’s amounts to conform to the current year’s presentation.
Management Estimates	Management Estimates Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based on such periodic evaluations.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash and cash equivalents to include cash in financial institutions and money market funds, and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Our cash and cash equivalents are governed by our investment policy as approved by our Board of Directors. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.
Marketable Securities	Marketable Securities The Company did not have marketable securities at December 31, 2016. The Company’s marketable securities at December 31, 2015 primarily consisted of corporate debt securities and exchange-traded funds. Our marketable securities are governed by our investment policy as approved by our Board of Directors. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices or net asset value. Unrealized temporary adjustments to fair value are included in a separate component of stockholders’ equity as unrealized gains and losses and reported as a component of accumulated other comprehensive income (loss). No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Fair Value of Other Financial Instruments	Fair Value of Other Financial Instruments The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, trade accounts payable, and our long-term debt. The carrying amounts of these financial instruments, other than marketable securities and our long-term debt, are representative of their respective fair values due to their relatively short maturities. The Company has not been able to measure the fair value of long-term debt due to a very limited marketplace having little or no market activity for this debt placement but given the change in the Company’s credit risk, the Company believes the fair value of long-term debt is below its carrying value. As discussed above, marketable securities are recorded at fair value.
Concentration of Credit Risk	Credit Risk : Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company’s excess cash is invested in accordance with the investment policy approved by our Board of Directors that seeks a combination of both liquidity and safety of principal using diversification of investments, through investments such as investment grade corporate debt securities with varying maturities. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, and marketable securities. Customers: We launched our first Impede Technology product, Nexafed®, in the United States in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. Our accounts receivable arise from our sales of our Nexafed product line and represent amounts due from wholesalers in the health care and pharmaceuticals industries and from chain drug stores. The Company has performed a credit evaluation of its customers and may maintain an allowance for potentially uncollectable accounts. We have not experienced any losses on uncollectable accounts in 2016 or 2015. 10 10 Customer 2016 2015 Rite Aid Corporation 55 % 54 % Cardinal Health, Inc. 13 % 14 % McKesson Corporation 10 % * Trade accounts receivable from certain of our customers at December 31, 2016 and 2015 accounting for 10% or more of our gross accounts receivable is presented below. Trade accounts receivable from customers designated with an ” ** ” accounted for less than 10% of our gross trade accounts receivable. Customer 2016 2015 AmerisourceBergen Corporation 35 % ** McKesson Corporation 24 % 11 % Cardinal Health, Inc. 19 % ** The Kroger Co. 18 % ** Rite Aid Corporation ** 68 %
Inventories	Inventories Inventories at December 31, 2016 consist of raw materials to be used in the manufacture to integrate Impede 2.0 technology into our commercially available Nexafed 30mg tablets, and finished goods held for distribution and sale on our Nexafed® product line. Inventories at December 31, 2015 consisted of finished goods held for distribution and sale on our Nexafed® product line. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). The Company writes down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results. Our purchases of active pharmaceutical ingredients and raw materials required for our development and clinical trial manufacture of product candidates utilizing our Aversion®, Impede® or Limitx Technologies are expensed as incurred.
Property, Plant and Equipment	Property, plant and equipment are stated at cost, less accumulated depreciation. We have no leasehold improvements. Betterments are capitalized and maintenance and repairs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation is removed from the respective accounts. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. depreciable assets are: 10 40 Land and improvements 20 40 Machinery and equipment 7 10 Scientific equipment 5 10 Computer hardware and software 3 10
Debt Issuance Costs and Debt Discount	Deferred Debt Issuance Costs and Debt Discount Deferred debt issuance costs include costs of debt financing undertaken by the Company, including legal fees, placement fees and other direct costs of the financing. Debt discount is the value attributable to warrants issued in conjunction with the financing. Debt issuance costs and debt discount are amortized into interest expense over the term of the related debt using the effective interest method. See Recent Accounting Pronouncements
License Fees	License Fee Revenue In December 2014, the Company entered into an agreement with Purdue Pharma to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered on the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering into an agreement whereby Acura conceded Purdue’s claim of priority in exchange for certain financial consideration to Acura including an immediate non-refundable payment of $ 500 250 In January 2015, the Company entered into a Collaboration and License Agreement to commercialize Oxaydo tablets (formerly known as Oxecta) utilizing our Aversion® Technology with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”). Egalet paid us $5.0 million upon signing the Egalet Agreement In October 2016, the Company entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using two of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm paid us $ 3.5
Milestone Revenue	Milestone Revenue Milestone revenue is contingent upon the achievement of certain pre-defined events in the development agreements. Milestone payments are recognized as revenue upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to that milestone. Milestone payments are triggered either by the results of our research and development efforts or by events external to us, such as regulatory approval to market a product. As such, the milestones are substantially at risk at the inception of an agreement, and the amounts of the payments assigned thereto are commensurate with the milestone achieved. In addition, upon the achievement of a milestone event, we have no future performance obligations related to that milestone payment. Each milestone payment is non-refundable and non-creditable when made and is recognized as revenue when received. In October 2015, Egalet paid us a $ 2.5
Collaboration Revenue	Collaboration Revenue Collaboration revenue is derived from reimbursement of development expenses, such as under our agreement with Bayer, and are recognized when costs are incurred pursuant to the agreements. The ongoing research and development services being provided under the collaboration are priced at fair value based upon the reimbursement of expenses incurred pursuant to the collaboration agreements. We recognized $ 392
Royalty Revenue	Royalty Revenue In connection with our Collaboration and License Agreement with Egalet to commercialize Oxaydo tablets we will receive a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year over the term of the agreement (excluding net sales resulting from any co-promotion efforts by us). We recognize royalty revenue each calendar quarter based on net sales reported to us by Egalet in accordance with the agreement. Egalet’s first commercial sale of Oxaydo occurred in October 2015 and we have recorded royalties of $149 thousand and $ 5
Product Sales	Product Sales Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. We sell our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products are sold subject to the right of return usually for a period of up to twelve months after the product expiration. Both products had an initial shelf life of twenty-four months from the date of manufacture, which shelf life has been extended to thirty-six months for Nexafed product supplied to us during 2016 from one of the Company’s contract manufacturers. Given the limited sales history of our Nexafed products, we could not reliably estimate expected returns of the product at the time of shipment to certain customers. During 2014, we continued deferring the recognition of revenue. During the first quarter of 2015, we determined we had obtained sufficient sales returns history to reasonably estimate future product returns from those customers. We recorded a one-time adjustment in the first quarter of 2015 to recognize revenue that had previously been deferred, resulting in additional net revenues of $ 314 120 255 304 205
Advertising Costs	Advertising Costs The Company records the cost of its advertising efforts when services are performed or goods are delivered.
Shipping and Handling Costs	Shipping and Handling Costs The Company records shipping and handling costs in selling expenses. The amounts recorded from the sales of Nexafed® were not material.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets such as the intangible asset and property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of the assets to be held and used is measured by a comparison of the carrying amount of the asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying value of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. We recorded an impairment charge of $ 82
Research and Development Activities	Research and Development Activities Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO’s based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. During 2015, we entered into a cancelable arrangement for contract manufacturing services on a project to integrate Impede 2.0 technology into our commercially available Nexafed 30mg tablet while moving supply to an alternate contract manufacturer. Approximately $ 50 0.2
Share-based Compensation	Share-based Compensation We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 12. We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost. Our share-based compensation expense recognized in the Company’s results of operations from all types of instruments issued comprised the following (in thousands): Year ended December 31, 2016 2015 Research and development: Stock option awards $ 167 $ 158 RSU awards - - $ 167 $ 158 Selling, general and administrative: Stock option awards 301 384 RSU awards 143 95 $ 444 $ 479 Total share-based compensation expense $ 611 $ 637
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that, under GAAP, are included in comprehensive income (loss), but excluded from net income (loss) as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company’s other comprehensive income (loss) is composed of unrealized gains (losses) on certain holdings of marketable securities, net of any realized gains (losses) included in net income (loss).
Income Taxes	Income Taxes We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and the income tax basis of assets and liabilities and are measured using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At December 31, 2016 and 2015, 100% of all remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.
Earnings Per Share (“EPS”)	Earnings Per Share (“EPS”) Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 12). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2016 or 2015 as the Company reported a net loss for the years and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive. Years ended December 31, 2016 2015 EPS – basic Numerator: net loss $ (7,388) $ (4,989) Denominator (weighted): Common shares 11,834 10,777 Vested RSUs 36 19 Basic weighted average shares outstanding 11,870 10,796 EPS - basic $ (0.62) $ (0.46) EPS – assuming dilution Numerator: net loss $ (7,388) $ (4,989) Denominator (weighted): Common shares 11,834 10,777 Vested RSUs 36 19 Stock options - - Common stock warrants - - Diluted weighted average shares outstanding 11,870 10,796 EPS - diluted $ (0.62) $ (0.46) Excluded dilutive securities: Common stock issuable (non weighted): Stock options 1,397 1,198 Common stock warrants 60 60 Total excluded potentially dilutive shares 1,457 1,258

SUMMARY OF SIGNIFICANT ACCOUN26

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Concentration of Risk, by Risk Factor	10 10 Customer 2016 2015 Rite Aid Corporation 55 % 54 % Cardinal Health, Inc. 13 % 14 % McKesson Corporation 10 % * Trade accounts receivable from certain of our customers at December 31, 2016 and 2015 accounting for 10% or more of our gross accounts receivable is presented below. Trade accounts receivable from customers designated with an ” ** ” accounted for less than 10% of our gross trade accounts receivable. Customer 2016 2015 AmerisourceBergen Corporation 35 % ** McKesson Corporation 24 % 11 % Cardinal Health, Inc. 19 % ** The Kroger Co. 18 % ** Rite Aid Corporation ** 68 %
Estimated Lives of Major Classification of Depreciable Assets	The estimated useful lives of the major classification of depreciable assets are: 10 40 Land and improvements 20 40 Machinery and equipment 7 10 Scientific equipment 5 10 Computer hardware and software 3 10
Non-Cash Share-Based Compensation Expense	Our share-based compensation expense recognized in the Company’s results of operations from all types of instruments issued comprised the following (in thousands): Year ended December 31, 2016 2015 Research and development: Stock option awards $ 167 $ 158 RSU awards - - $ 167 $ 158 Selling, general and administrative: Stock option awards 301 384 RSU awards 143 95 $ 444 $ 479 Total share-based compensation expense $ 611 $ 637
Computation of Diluted Earnings (loss) Per Share	A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands, except per share data): Years ended December 31, 2016 2015 EPS – basic Numerator: net loss $ (7,388) $ (4,989) Denominator (weighted): Common shares 11,834 10,777 Vested RSUs 36 19 Basic weighted average shares outstanding 11,870 10,796 EPS - basic $ (0.62) $ (0.46) EPS – assuming dilution Numerator: net loss $ (7,388) $ (4,989) Denominator (weighted): Common shares 11,834 10,777 Vested RSUs 36 19 Stock options - - Common stock warrants - - Diluted weighted average shares outstanding 11,870 10,796 EPS - diluted $ (0.62) $ (0.46) Excluded dilutive securities: Common stock issuable (non weighted): Stock options 1,397 1,198 Common stock warrants 60 60 Total excluded potentially dilutive shares 1,457 1,258

INVESTMENTS IN MARKETABLE SEC27

INVESTMENTS IN MARKETABLE SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Marketable securities	Investments in marketable securities at December 31, 2015 consisted of the following (in millions): December 31, 2015 Marketable securities: Corporate bonds — maturing within 1 year $ 3.1 Corporate bonds — maturing after 1 year and through March 2017 0.4 Exchange-traded funds 7.3 Total marketable securities $ 10.8
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions): December 31, 2015 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value Available-for-sale: Corporate bonds $ 3.6 $ - $ (0.1) $ 3.5 Exchange-traded funds 7.3 - - 7.3 Total - Current $ 10.9 $ - $ (0.1) $ 10.8
Fair Value, Assets Measured on Recurring Basis	Our assets measured at fair value or disclosed at fair value on a recurring basis as at December 31, 2015 consisted of the following (in millions): December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Corporate bonds 3.5 - 3.5 - Exchange-traded funds 7.3 7.3 - - Total $ 10.8 $ 7.3 $ 3.5 $ -

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories are summarized as follows (in thousands): December 31, 2016 2015 Raw materials $ 98 $ - Finished goods 243 346 Total inventory 341 346 Less: inventory reserve - finished goods (32) (70) Net inventory $ 309 $ 276
Inventory Reserve	Inventory reserve activity during the years ended December 31, 2016 and 2015 was as follows (in thousands): 2016 2015 Beginning of year $ 70 $ - Reserve expense - raw and packaging - 260 Reserve expense - finished goods 26 70 96 330 Inventory write-offs - raw and packaging - (260) Inventory write-offs - finished goods (64) - End of year $ 32 $ 70

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property Plant and Equipment	Property, plant and equipment are summarized as follows (in thousands): December 31, 2016 2015 Building and improvements $ 1,273 $ 1,265 Scientific equipment 598 598 Computer hardware and software 109 124 Machinery and equipment 568 508 Land and improvements 162 162 Other personal property 70 70 Office equipment 27 27 2,807 2,754 Less: impairment reserve (82) (-) Less: accumulated depreciation (1,858) (1,741) Total property, plant and equipment, net $ 867 $ 1,013

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accurued Expenses	Accrued expenses are summarized as follows (in thousands): December 31, 2016 2015 Professional services $ 232 $ 171 Other fees and services 95 64 Payroll, payroll taxes and benefits 116 101 Clinical and regulatory services 233 92 Marketing, advertising, and promotion 10 115 Property taxes 16 15 Franchise taxes 1 6 $ 703 $ 564

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule Of Fair Value Of Warrants	The fair value of the warrants was determined using the Black-Scholes option-pricing model. Significant assumptions used in the Black-Scholes model were: Expected dividend yield 0.0 % Risk-free interest rate 2.4 % Expected volatility 92 % Expected term (years) 7
Schedule of Debt	Our debt at December 31, 2016 is summarized below (in thousands): Current Debt Current Long-term Total Balance at Dec 31, 2015 $ 2,320 $ 5,720 $ 8,040 Principal payments (2,540) - (2,540) Classification 2,741 (2,741) - Balance at Dec 31, 2016 $ 2,521 $ 2,979 $ 5,500 Debt Discount Current Long-term Total Balance at Dec 31, 2015 $ - $ (193) $ (193) Amortization expense - 95 95 Classification (98) 98 - Balance at Dec 31, 2016 $ (98) $ - $ (98) Deferred Debt Issuance Costs Current Long-term Total Balance at Dec 31, 2015 $ - $ (97) $ (97) Amortization expense - 50 50 Classification (47) 47 - Balance at Dec 31, 2016 $ (47) $ - $ (47) Current Debt, net at Dec 31, 2016 $ 2,376 $ 2,979 $ 5,355
Schedule of Interest Expense	2016 2015 Interest expense: Term Loan $ 748 $ 971 Debt discount 95 121 Debt issue costs 50 65 Total interest expense $ 893 $ 1,157
Schedule Of Long Term Debt Future Principal Payments Year	The annual principal payments of the debt at December 31, 2016 are as follows: Annual Principal Payments Year (in thousands) 2017 $ 2,521 2018 2,979 Total $ 5,500

COMMON STOCK WARRANTS (Tables)

COMMON STOCK WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders Equity Note [Abstract]
Schedule Of Common Stock Warrant Activity	Our warrant activity during the years ended December 31, 2016 and 2015 is shown below (in thousands except price data): December 31, 2016 2015 WAvg WAvg Exercise Exercise Number Price Number Price Outstanding, beginning 60 $ 2.52 60 $ 7.98 Issued - - - - Exercised - - - - Expired - - - - Modification - - - (5.46) Outstanding, ending 60 $ 2.52 60 $ 2.52

EMPLOYEE BENEFIT PLANS (Tables)

EMPLOYEE BENEFIT PLANS (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	A summary of our stock option plans as of December 31, 2016 and 2015 and for the years then ended consisted of the following (in thousands except exercise price): Years Ended December 31, 2016 2015 Weighted Weighted Number Average Average of Exercise Number of Exercise Options Price Options Price Outstanding, beginning 1,198 $ 15.67 911 $ 20.70 Granted 199 0.92 315 2.01 Exercised - - - - Forfeited or expired - - (28) 26.75 Outstanding, ending 1,397 $ 15.67 1,198 $ 15.67 Exercisable, ending 1,062 $ 17.41 814 $ 22.04
Schedule of Nonvested Share Activity	The following table summarizes information about nonvested stock options outstanding at December 31, 2016 (in thousands except price data): Number of Weighted Options Not Average Fair Exercisable Value Outstanding at December 31, 2015 384 $ 1.85 Granted 199 0.92 Vested (248) 1.89 Forfeited - - Outstanding at December 31, 2016 335 $ 1.18
Schedule of fair value of the warrants	The assumptions used in the Black-Scholes model to determine fair value for the 2016 and 2015 stock option grants were: 2016 2015 Expected dividend yield 0.0 % 0.0 % Risk-free interest rates 2.3 % 2.2 % Average expected volatility 85 % 89 % Expected term (years) 10 10 Weighted average grant date fair value $ 0.77 $ 1.72
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	A summary of the grants under the RSU Plans as of December 31, 2016 and 2015, and for the years then ended consisted of the following (in thousands): Years Ended December 31, 2016 2015 Number of Number of Number of Vested Number of Vested RSUs RSUs RSUs RSUs Outstanding, beginning 45 45 29 29 Granted 88 - 42 - Distributed (42) (42) (26) (26) Vested - 88 - 42 Forfeited or expired - - - - Outstanding, ending 91 91 45 45

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Provision for Income Taxes	The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows (in thousands): December 31, 2016 2015 Benefit at U.S. statutory 34% tax rate $ (2,512) $ (1,696) State taxes (benefit), net of federal effect 49 41 Research and development tax credits - - Share-based compensation 159 184 Other 2 11 Change in valuation allowance 2,302 1,460 Provision for income taxes $ - $ -
Components Of Deferred Tax Assets	As of December 31, 2016 we had federal research and development tax credits of approximately $ 1.2 0.2 The components of our deferred tax assets are as follows: December 31, 2016 2015 (in thousands) Deferred tax assets: Estimated future value of NOLs - Federal $ 47,192 $ 52,772 - State 2,135 2,050 Research and development tax credits 1,320 1,394 Share-based compensation 57 38 Other, net 332 368 Total deferred taxes 51,036 56,622 Valuation allowance (51,036) (56,622) Net deferred tax assets $ - $ -

SUPPLEMENTARY DATA - QUARTERL35

SUPPLEMENTARY DATA - QUARTERLY FINANCIAL DATA (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Selected Quarterly Financial Information [Abstract]
SUPPLEMENTARY DATA - QUARTERLY FINANCIAL DATA	For Three Month Periods Ended Mar. 31, June 30, Sept. 30, Dec. 31, 2016 2016 2016 2016 Net revenues $ 224 $ 257 $ 218 $ 3,765 Operating expenses 3,362 3,336 2,287 2,036 Operating (loss) income (3,138) (3,079) (2,069) 1,729 Net (loss) income $ (3,384) $ (3,288) $ (2,250) $ 1,534 Basic (loss) income per share $ (0.28) $ (0.28) $ (0.19) $ 0.13 Diluted (loss) income per share $ (0.28) $ (0.28) $ (0.19) $ 0.13 For Three Month Periods Ended Mar. 31, June 30, Sept. 30, Dec. 31, 2015 2015 2015 2015 Net revenues $ 5,357 $ 341 $ 210 $ 2,679 Operating expenses 3,845 2,739 2,615 3,389 Operating income (loss) 1,512 (2,398) (2,405) (710) Net loss $ 1,239 $ (2,663) $ (2,649) $ (916) Basic income (loss) per share $ 0.13 $ (0.28) $ (0.23) $ (0.08) Diluted income (loss) per share $ 0.13 $ (0.28) $ (0.23) $ (0.08)

OPERATIONS AND SUMMARY OF SIG36

OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Restricted Cash and Investments	$ 2,500								$ 2,500
Cash, Cash Equivalent And Marketable Securities	2,700								2,700
Working Capital Deficit	700								700
Retained Earnings (Accumulated Deficit), Total	(374,698)				$ (367,310)				(374,698)	$ (367,310)
Operating Income (Loss), Total	1,729	$ (2,069)	$ (3,079)	$ (3,138)	(710)	$ (2,405)	$ (2,398)	$ 1,512	(6,557)	(4,001)
Net Income (Loss) Attributable to Parent, Total	1,534	$ (2,250)	$ (3,288)	$ (3,384)	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	(7,388)	$ (4,989)
Debt Instrument, Debt Default, Amount	2,500								2,500
Oxford Term Loan Agreement [Member]
Debt Instrument, Debt Default, Amount	$ 2,500								$ 2,500

SUMMARY OF SIGNIFICANT ACCOUN37

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk by Risk Factor (Detail)	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015
Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Rite Aid Corporation | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	55.00%		54.00%
Rite Aid Corporation | Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage		[1]	68.00%
Cardinal Health, Inc. | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	13.00%		14.00%
Cardinal Health, Inc. | Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage	19.00%			[1]
AmerisourceBergen Corporation | Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage	35.00%			[1]
McKesson Corporation | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%			[2]
McKesson Corporation | Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage	24.00%		11.00%
Kroger Foods | Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage	18.00%			[1]
[1]	accounted for less than 10% of our gross trade accounts receivable.
[2]	accounted for less than 10% of our annual product sales.

SUMMARY OF SIGNIFICANT ACCOUN38

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of the Major Classification of Depreciable Assets (Detail)	12 Months Ended
	Dec. 31, 2016
Building and Building Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Building and Building Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Land Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Land Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Scientific Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Scientific Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Hardware and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Computer Hardware and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

SUMMARY OF SIGNIFICANT ACCOUN39

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Non-Cash Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 611	$ 637
Research and Development Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	167	158
Research and Development Expense | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	167	158
Research and Development Expense | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	0	0
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	444	479
Selling, General and Administrative | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	301	384
Selling, General and Administrative | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 143	$ 95

SUMMARY OF SIGNIFICANT ACCOUN40

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
EPS - basic
Numerator: net loss	$ 1,534	$ (2,250)	$ (3,288)	$ (3,384)	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	$ (7,388)	$ (4,989)
Denominator (weighted):
Common shares									11,834	10,777
Vested RSUs									36	19
Basic weighted average shares outstanding									11,870	10,796
EPS - basic	$ 0.13	$ (0.19)	$ (0.28)	$ (0.28)	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.62)	$ (0.46)
EPS - assuming dilution
Numerator: net loss	$ 1,534	$ (2,250)	$ (3,288)	$ (3,384)	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	$ (7,388)	$ (4,989)
Denominator (weighted):
Common shares									11,834	10,777
Vested RSUs									36	19
Stock options									0	0
Common stock warrants									0	0
Diluted weighted average shares outstanding									11,870	10,796
EPS - diluted	$ 0.13	$ (0.19)	$ (0.28)	$ (0.28)	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.62)	$ (0.46)
Common stock issuable (non weighted):
Total excluded potentially dilutive shares									1,457	1,258
Common stock warrants [Member]
Common stock issuable (non weighted):
Total excluded potentially dilutive shares									60	60
Employee Stock Option [Member]
Common stock issuable (non weighted):
Total excluded potentially dilutive shares									1,397	1,198

SUMMARY OF SIGNIFICANT ACCOUN41

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended		12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015	Jun. 30, 2015	Dec. 31, 2016	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Financing Receivable, Impaired [Line Items]
Royalty Revenue, Total						$ 149	$ 5
Other Revenue, Net						392	170
Sales Revenue, Goods, Net, Total						423	662
Professional and Contract Services Expense						200
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets				$ 162		162
Asset Impairment Charges				82		82	0
Research and Development Arrangement, Remaining Amount, Others				$ 50		50
Nexafed products [Member]
Financing Receivable, Impaired [Line Items]
Sales Revenue, Goods, Net, Total					$ 314
Revenue Recognition, Sales Returns, Reserve for Sales Returns					120	$ 304	$ 205
Related Parties Amount in Cost of Sales					$ 255
Kempharm Agreement [Member]
Financing Receivable, Impaired [Line Items]
Proceeds From Upfront Payment	$ 3,500
Egalet Ltd [Member]
Financing Receivable, Impaired [Line Items]
Loss Contingency, Settlement Agreement, Terms						Egalet paid us $5.0 million upon signing the Egalet Agreement
Proceeds from Milestone Payment On Agreement		$ 2,500
Sales Revenue, Net [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%
Sales Revenue, Net [Member] | Minimum [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%
Purdue Pharma [Member]
Financing Receivable, Impaired [Line Items]
Litigation Settlement, Expense			$ 250					$ 500

LICENSE, DEVELOPMENT, AND COM42

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) - USD ($)	Oct. 09, 2015	Mar. 16, 2017	Oct. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2017
License Development and Commercialization Agreement [Line Items]
Agreement Termination Notice Description				Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Termination does not affect a partys rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalets supply of Oxaydo for a transition period.
Retail Related Inventory, Total				$ 260,000
Amortization of Intangible Assets				207,000	$ 207,000
Subsequent Event [Member]
License Development and Commercialization Agreement [Line Items]
License Agreement Option Products Description		In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500,000 per product (for all product strengths). If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750,000 per product. If the territory is expanded after the payment of the $500,000 product option fee, a one-time $250,000 fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.
Pfizer Agreement
License Development and Commercialization Agreement [Line Items]
Payment for Termination				$ 2,000,000
Pfizer Agreement | Subsequent Event [Member]
License Development and Commercialization Agreement [Line Items]
Finite-Lived Intangible Asset, Useful Life		9 years 8 months 12 days
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months						$ 207,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two		$ 207,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three		207,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four		207,000
Egalet Agreement
License Development and Commercialization Agreement [Line Items]
Minimum Net Sales Reaching Description				one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Licenses Revenue	$ 5,000,000
Proceeds from Milestone Payment On Agreement	$ 2,500,000
Main Pointe Agreement [Member] | Subsequent Event [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		2,500,000
Asset Transferred, License Agreement		$ 425,000
Licensing Agreement, Royalty Percentage		7.50%
Main Pointe Agreement [Member] | Subsequent Event [Member] | UNITED KINGDOM
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 1,000,000
Main Pointe Agreement [Member] | Subsequent Event [Member] | JAPAN
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		500,000
Main Pointe Agreement [Member] | Subsequent Event [Member] | South Korea [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 250,000
Kempharm Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received			$ 3,500,000
Kempharm Agreement [Member] | Minimum
License Development and Commercialization Agreement [Line Items]
Additional Upfront Payment Receivable			$ 1,000,000

INVESTMENTS IN MARKETABLE SEC43

INVESTMENTS IN MARKETABLE SECURITIES - Summary of Investments in Marketable Securities (Detail) $ in Millions	Dec. 31, 2015USD ($)
Marketable securities:
Corporate bonds — maturing within 1 year	$ 3.1
Corporate bonds — maturing after 1 year and through March 2017	0.4
Total marketable securities	10.8
Exchange-traded funds
Marketable securities:
Total marketable securities	$ 7.3

INVESTMENTS IN MARKETABLE SEC44

INVESTMENTS IN MARKETABLE SECURITIES - Fair Value and Unrealized Gains (Losses) related to the Company’s Available-For-Sale Securities (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Available-for-sale:
Cost	$ 10.9
Gross Unrealized Gains	0
Gross Unrealized Losses	(0.1)
Fair Value	10.8
Corporate Bonds
Available-for-sale:
Cost	3.6
Gross Unrealized Gains	0
Gross Unrealized Losses	(0.1)
Fair Value	3.5
Exchange-traded funds
Available-for-sale:
Cost	7.3
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	$ 7.3

INVESTMENTS IN MARKETABLE SEC45

INVESTMENTS IN MARKETABLE SECURITIES - Assets Measured at Fair Value or Disclosed at Fair Value on Recurring Basis (Detail) $ in Millions	Dec. 31, 2015USD ($)
Assets:
Total marketable securities	$ 10.8
Corporate bonds
Assets:
Total marketable securities	3.5
Exchange-traded funds
Assets:
Total marketable securities	7.3
Fair Value, Inputs, Level 1
Assets:
Total marketable securities	7.3
Fair Value, Inputs, Level 1 | Corporate bonds
Assets:
Total marketable securities	0
Fair Value, Inputs, Level 1 | Exchange-traded funds
Assets:
Total marketable securities	7.3
Fair Value, Inputs, Level 2
Assets:
Total marketable securities	3.5
Fair Value, Inputs, Level 2 | Corporate bonds
Assets:
Total marketable securities	3.5
Fair Value, Inputs, Level 2 | Exchange-traded funds
Assets:
Total marketable securities	0
Fair Value, Inputs, Level 3
Assets:
Total marketable securities	0
Fair Value, Inputs, Level 3 | Corporate bonds
Assets:
Total marketable securities	0
Fair Value, Inputs, Level 3 | Exchange-traded funds
Assets:
Total marketable securities	$ 0

INVESTMENTS IN MARKETABLE SEC46

INVESTMENTS IN MARKETABLE SECURITIES - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Accumulated Other Comprehensive Income (Loss)
Investment In Marketable Securities [Line Items]
Unrealized losses on securities	$ 65

INVENTORIES - Schedule of Inven

INVENTORIES - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 98	$ 0
Finished goods	243	346
Total inventory	341	346
Less: inventory reserve - finished goods	(32)	(70)	$ 0
Net inventory	$ 309	$ 276

INVENTORIES - Inventory Reserve

INVENTORIES - Inventory Reserve (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Beginning of year	$ 70	$ 0
Reserve expense - raw and packaging	0	260	$ 260
Reserve expense - finished goods	26	70
Inventory Reserve Expense	96	330
Inventory write-offs - raw and packaging	0	(260)
Inventory write-offs - finished goods	(64)	0
End of year	$ 32	$ 70	$ 0

INVENTORIES - Additional Inform

INVENTORIES - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Inventory Reserve Expense Raw and Packagings	$ 0	$ 260	$ 260

PROPERTY, PLANT AND EQUIPMENT50

PROPERTY, PLANT AND EQUIPMENT (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,807	$ 2,754
Less: impairment reserve	(82)	0
Less: accumulated depreciation	(1,858)	(1,741)
Total property, plant and equipment, net	867	1,013
Building and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,273	1,265
Scientific equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	598	598
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	109	124
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	568	508
Land and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	162	162
Other personal property
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	70	70
Office equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 27	$ 27

PROPERTY, PLANT AND EQUIPMENT -

PROPERTY, PLANT AND EQUIPMENT - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation	$ 0.1	$ 0.1

ACCRUED EXPENSES (Detail)

ACCRUED EXPENSES (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounts Payable and Accrued Liabilities [Line Items]
Professional services	$ 232	$ 171
Other fees and services	95	64
Payroll, payroll taxes and benefits	116	101
Clinical and regulatory services	233	92
Marketing, advertising, and promotion	10	115
Property taxes	16	15
Franchise taxes	1	6
Total	$ 703	$ 564

DEBT - Fair Value of Warrants u

DEBT - Fair Value of Warrants using the Black-Scholes option-pricing model - (Detail) - Warrant [Member]	12 Months Ended
	Dec. 31, 2016
Fair Value Of Warrants [Line Items]
Expected dividend yield	0.00%
Risk-free interest rates	2.40%
Expected volatility	92.00%
Expected term (years)	7 years

DEBT - Summary of Debt (Detail)

DEBT - Summary of Debt (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Current Debt
Balance at Dec 31, 2015	$ 8,040
Principal payments	(2,540)
Classification	0
Balance at Dec 31, 2016	5,500
Debt Discount
Balance at Dec 31, 2015	(193)
Amortization expense	95
Classification	0
Balance at Dec 31, 2016	(98)
Deferred Debt Issuance Costs
Balance at Dec 31, 2015	(97)
Amortization expense	50
Classification	0
Balance at Dec 31, 2016	(47)
Current Debt, net at Dec 31, 2016	5,355
Long-term [Member]
Current Debt
Balance at Dec 31, 2015	5,720
Principal payments	0
Classification	(2,741)
Balance at Dec 31, 2016	2,979
Debt Discount
Balance at Dec 31, 2015	(193)
Amortization expense	95
Classification	98
Balance at Dec 31, 2016	0
Deferred Debt Issuance Costs
Balance at Dec 31, 2015	(97)
Amortization expense	50
Classification	47
Balance at Dec 31, 2016	0
Current Debt, net at Dec 31, 2016	2,979
Current [Member]
Current Debt
Balance at Dec 31, 2015	2,320
Principal payments	(2,540)
Classification	2,741
Balance at Dec 31, 2016	2,521
Debt Discount
Balance at Dec 31, 2015	0
Amortization expense	0
Classification	(98)
Balance at Dec 31, 2016	(98)
Deferred Debt Issuance Costs
Balance at Dec 31, 2015	0
Amortization expense	0
Classification	(47)
Balance at Dec 31, 2016	(47)
Current Debt, net at Dec 31, 2016	$ 2,376

DEBT - Interest Expense (Detail

DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Interest expense:
Term Loan	$ 748	$ 971
Debt discount	95	121
Debt issue costs	50	65
Total interest expense	$ 893	$ 1,157

DEBT - Long-Term Debt (Detail)

DEBT - Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
2,017	$ 2,521
2,018	2,979
Total	$ 5,500	$ 8,040

DEBT - Additional Information (

DEBT - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Jan. 07, 2015	Oct. 31, 2016	Apr. 18, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 27, 2013
Debt Instrument [Line Items]
Debt instrument principal amount							$ 10,000
Debt default long term debt percentage							13.35%
Debt Instrument, Maturity Date				Dec. 1, 2018
Debt instrument, fee amount				$ 50
Debt consulting placement fee				100
Debt related commitment fees and debt issuance costs				50	$ 65
Debt instrument unamortized discount				98	$ 193
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 2.52	$ 7.98
Debt instrument Cash Maintenance	$ 2,500
Repayments of Debt				2,540	$ 1,960
Debt Instrument, Periodic Payment				260
Debt instrument, periodic payment, principal				$ 2,540
Debt Instrument, Interest Rate, Effective Percentage				10.16%
Proceeds from Issuance or Sale of Equity		$ 6,000	$ 13,000
Term Loan [Member]
Debt Instrument [Line Items]
Debt related commitment fees and debt issuance costs				$ 231
Interest Payable, Current				559	$ 387
Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage							8.35%
Repayments of Debt	$ 5,000	5,000
Proceeds from Issuance or Sale of Equity		2,500
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.98
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52
Proceeds from Issuance or Sale of Equity		$ 3,000
Warrant
Debt Instrument [Line Items]
Debt instrument unamortized discount				$ 400
Warrants to purchase common stock				60
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 7.98
Warrants, expiry date				December 27, 2020
Additions To Debt Instrument Unamortized Discount	$ 33
First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument periodic payment terms balloon payment to be paid				$ 795
Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage				1.00%

EQUITY FINANCINGS - Additional

EQUITY FINANCINGS - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended		6 Months Ended	12 Months Ended
	Oct. 31, 2016	Apr. 18, 2013	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2016
Equity Financing [Line Items]
Proceeds from sale of common stock	$ 6,000	$ 13,000
Sale leaseback transaction, transaction costs, financing activities				$ 8
Sale leaseback transaction, net proceeds, financing activities				$ 217
Placement agency reimbursed for expenses			$ 496
Common Stock, Par or Stated Value Per Share				$ 0.01	$ 0.01
Common Stock [Member]
Equity Financing [Line Items]
Proceeds from sale of common stock				$ 225
Stock issued during period, shares, new issues				54
Placement Agency Agreement [Member]
Equity Financing [Line Items]
Stock issued during period, shares, new issues			1,958
Share price			$ 0.01
Proceeds from issuance of private placement			$ 7,000
Description for repayment of placement agent			paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering
Placement agency reimbursed for expenses			$ 35
Common Stock, Par or Stated Value Per Share			$ 1
Securities Purchase Agreement [Member]
Equity Financing [Line Items]
Stock issued during period, shares, new issues			1,958
Share price			$ 3.90
Proceeds from issuance of private placement			$ 7,640

COMMON STOCK WARRANTS - Schedul

COMMON STOCK WARRANTS - Schedule Of Common Stock Warrant Activity (Detail) - Warrant [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Number of Options
Number of Options Outstanding, beginning	60	60
Number of Options, Issued	0	0
Number of Options, Exercised	0	0
Number of Options, Expired	0	0
Number of Options, Modification	0	0
Number of Options Outstanding, ending	60	60
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 2.52	$ 7.98
Issued	0	0
Exercised	0	0
Expired	0	0
Modification	0	(5.46)
Weighted Average Exercise Price, ending	$ 2.52	$ 2.52

COMMON STOCK WARRANTS - Additio

COMMON STOCK WARRANTS - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.52	$ 7.98
Secured Debt				$ 10
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.98

EMPLOYEE BENEFIT PLANS - Stock

EMPLOYEE BENEFIT PLANS - Stock Option Award Activity (Detail) - Stock Option Plan [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	1,198	911
Number of Options, Granted	199	315
Number of Options, Exercised	0	0
Number of Options, Forfeited or expired	0	(28)
Number of Options Outstanding, ending	1,397	1,198
Number of Options exercisable	1,062	814
Weighted Average Exercise Price, beginning	$ 15.67	$ 20.70
Weighted Average Exercise Price, Granted	0.92	2.01
Weighted Average Exercise Price, Exercised	0	0
Weighted Average Exercise Price, Forfeited or expired	0	26.75
Weighted Average Exercise Price, ending	15.67	15.67
Weighted Average Exercise Price, Options exercisable	$ 17.41	$ 22.04

EMPLOYEE BENEFIT PLANS - Summar

EMPLOYEE BENEFIT PLANS - Summary of Information about Non Vested Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Summary Of Information About Non Vested Stock Options Disclosure [Line Items]
Outstanding, beginning | shares	384
Granted | shares	199
Vested | shares	(248)
Forfeited | shares	0
Outstanding, ending | shares	335
Outstanding beginning, Weighted Average Fair Value | $ / shares	$ 1.85
Granted, Weighted Average Fair Value | $ / shares	0.92
Vested, Weighted Average Fair Value | $ / shares	1.89
Forfeited, Weighted Average Fair Value | $ / shares	0
Outstanding ending, Weighted Average Fair Value | $ / shares	$ 1.18

EMPLOYEE BENEFIT PLANS - Assump

EMPLOYEE BENEFIT PLANS - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Detail) - Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Risk-free interest rates	2.30%	2.20%
Average expected volatility	85.00%	89.00%
Expected term (years)	10 years	10 years
Weighted average grant date fair value	$ 0.77	$ 1.72

EMPLOYEE BENEFIT PLANS - Summ64

EMPLOYEE BENEFIT PLANS - Summary of RSU Plan (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	384
Granted	199
Vested	248
Forfeited or expired	0
Outstanding, ending	335	384
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	45	29
Granted	88	42
Distributed	(42)	(26)
Vested	0	0
Forfeited or expired	0	0
Outstanding, ending	91	45
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	45	29
Granted	0	0
Distributed	(42)	(26)
Vested	88	42
Forfeited or expired	0	0
Outstanding, ending	91	45

EMPLOYEE BENEFIT PLANS - Additi

EMPLOYEE BENEFIT PLANS - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	Jan. 03, 2017	Jan. 04, 2016	Jun. 30, 2014	May 01, 2014	Jan. 02, 2015	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2015
Employee Benefit Plans Disclosure [Line Items]
Aggregate intrinsic value of the option awards vested								$ 6
Unrecognized compensation cost on unvested option awards outstanding						$ 400
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution		66
401(k) and Profit-Sharing Plan
Employee Benefit Plans Disclosure [Line Items]
Maximum basic contribution percentage per employee on annual earnings						80.00%
2014 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		1			26
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution		42			4
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award						241
2014 Restricted Stock Unit Award Plan [Member] | Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		9		22	7
2014 Restricted Stock Unit Award Plan [Member] | Distributed In Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		42			26
2014 Restricted Stock Unit Award Plan [Member] | Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		33			19
2014 Restricted Stock Unit Award Plan [Member] | Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		22		7	10
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%	50.00%		25.00%		25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description		stock, for up to 40%			stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value							$ 26
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution		2
Deferred Compensation Arrangement with Individual, Recorded Liability						$ 27		$ 45
2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	1
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution	66
2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	18
2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Distributed In Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	67
2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	49
2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	60
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description	stock, for up to 40%
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution	1

INCOME TAXES - Provision for In

INCOME TAXES - Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Provision For Income Taxes [Line Items]
Benefit at U.S. statutory 34% tax rate	$ (2,512)	$ (1,696)
State taxes (benefit), net of federal effect	49	41
Research and development tax credits	0	0
Share-based compensation	159	184
Other	2	11
Change in valuation allowance	2,302	1,460
Provision for income taxes	$ 0	$ 0

INCOME TAXES - Components of Ou

INCOME TAXES - Components of Our Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
- Federal	$ 47,192	$ 52,772
- State	2,135	2,050
Research and development tax credits	1,320	1,394
Share-based compensation	57	38
Other, net	332	368
Total deferred taxes	51,036	56,622
Valuation allowance	(51,036)	(56,622)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Federal income tax benefits	$ 47,200
Federal NOLs	$ 138,800
U.S. statutory tax rate	34.00%
Research and development tax credits	$ 1,320	$ 1,394
State income tax benefits	2,100
Valuation allowance, deferred tax asset, change in amount	5,600	$ 600
Federal Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	1,200
Indiana State Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	$ 200
Maximum
Income Tax Disclosure [Line Items]
NOL expiration year	2,036
Minimum
Income Tax Disclosure [Line Items]
NOL expiration year	2,017

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Jun. 30, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2014USD ($)
Commitments and Contingencies Disclosure [Line Items]
Accrued Cost Sharing Expenses Clinical Studies		$ 95,000
Purdue Pharma [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Expense	$ 250,000		$ 500,000
Pennsylvania State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed		200
New Jersey State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed		150
Number of lawsuits served		50
California State
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs served in a single complaint		445
Palatine Illinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space		$ 25,000
Lease expiring date		March 31, 2017

SUBSEQUENT EVENT - Additional I

SUBSEQUENT EVENT - Additional Information (Detail) - Subsequent Event [Member]	1 Months Ended
	Mar. 16, 2017USD ($)
Subsequent Event [Line Items]
License Agreement Option Products Description	In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500,000 per product (for all product strengths). If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750,000 per product. If the territory is expanded after the payment of the $500,000 product option fee, a one-time $250,000 fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.
Main Pointe Agreement [Member]
Subsequent Event [Line Items]
Proceeds from License Fees Received	$ 2,500,000
Asset Transferred, License Agreement	$ 425,000
Licensing Agreement, Royalty Percentage	7.50%
Main Pointe Agreement [Member] | UNITED KINGDOM
Subsequent Event [Line Items]
Proceeds from License Fees Received	$ 1,000,000
Main Pointe Agreement [Member] | JAPAN
Subsequent Event [Line Items]
Proceeds from License Fees Received	500,000
Main Pointe Agreement [Member] | South Korea [Member]
Subsequent Event [Line Items]
Proceeds from License Fees Received	$ 250,000

SUPPLEMENTARY DATA - QUARTERL71

SUPPLEMENTARY DATA - QUARTERLY FINANCIAL DATA (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Quarterly Financial Information [Line Items]
Net revenues	$ 3,765	$ 218	$ 257	$ 224	$ 2,679	$ 210	$ 341	$ 5,357	$ 4,464	$ 8,587
Operating expenses	2,036	2,287	3,336	3,362	3,389	2,615	2,739	3,845	11,021	12,588
Operating (loss) income	1,729	(2,069)	(3,079)	(3,138)	(710)	(2,405)	(2,398)	1,512	(6,557)	(4,001)
Net (loss) income	$ 1,534	$ (2,250)	$ (3,288)	$ (3,384)	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	$ (7,388)	$ (4,989)
Basic (loss) income per share	$ 0.13	$ (0.19)	$ (0.28)	$ (0.28)	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.62)	$ (0.46)
Diluted (loss) income per share	$ 0.13	$ (0.19)	$ (0.28)	$ (0.28)	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.62)	$ (0.46)